Esophageal Dilation denied as experimental or investigational by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for esophageal dilation are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Esophageal Dilation as Experimental

Esophageal dilation in its standard forms — balloon dilation and bougie dilation — has been performed for decades and is considered standard of care for esophageal strictures, rings, achalasia, and related conditions. An "experimental or investigational" denial for esophageal dilation typically arises in one of three scenarios: (1) the specific technique used (e.g., peroral endoscopic myotomy, or POEM, for achalasia) is newer and BCBS's medical policy has not yet categorized it as established; (2) the indication is one that BCBS's policy restricts to an investigational classification; or (3) a coding or documentation error caused the claim to be routed to the experimental/investigational policy incorrectly.

## Why This Denial Is Appealable

Medical policies classifying a procedure as experimental must be based on the current state of the published clinical literature and the positions of recognized professional societies. Major gastroenterology and surgical societies have published guidance on esophageal dilation procedures, and that guidance can be used to challenge an outdated or incorrect experimental classification. The appeal should document that the procedure is recognized as an accepted treatment by the relevant specialty organizations and is supported by the published literature.

## Federal Appeal Framework

• Internal appeal (ERISA §503 / ACA §2719): File within the deadline in the denial letter. Reference the applicable professional society positions (e.g., the American Society for Gastrointestinal Endoscopy or the American College of Gastroenterology) and the published literature.
• External review (ACA §2719): After a final internal denial, escalate to an Independent Review Organization within approximately four months. IRO reviewers are required to assess whether the experimental/investigational classification was correctly applied.
• Expedited track: Request expedited review if the patient is experiencing significant symptoms (dysphagia, weight loss, aspiration risk).

## Concrete Appeal Steps

1. Obtain BCBS's current experimental/investigational policy for the specific procedure code from the provider portal. 2. Identify the specific technique used and the indication documented in the procedure report. 3. Locate current professional society guidelines or position statements addressing the procedure for this indication. 4. Have the proceduralist draft a letter addressing the experimental/investigational classification directly. 5. Submit the internal appeal with the documentation package and society-guideline references. 6. If denied, escalate to IRO external review.

## Documentation to Gather

• Procedure report: The complete operative or endoscopy note confirming the specific technique, approach, and instruments used.
• Diagnosis documentation: Chart notes establishing the condition requiring dilation and its severity (symptom duration, dysphagia frequency, prior interventions).
• Professional society guidelines: Current position statements or clinical practice guidelines from relevant gastroenterology or thoracic surgery societies supporting the procedure for this indication. Reference the organization and publication generically; do not fabricate statistics.
• Proceduralist letter: A detailed letter from the performing physician explaining why the procedure is clinically accepted practice, not experimental, for this patient's condition — citing the guideline organizations by name.
• Literature support: Published peer-reviewed references (author, journal, year — no fabricated statistics) supporting the use.

## Criteria-Mapping Structure

Copy each criterion from BCBS's experimental/investigational policy verbatim into the left column of a table. In the right column, cite the specific clinical documentation, guideline reference, or published literature that satisfies or rebuts each criterion.